Verinata Health Announces Agreement with Teva Pharmaceutical Industries in Collaboration with MOR Institute for Medical Data to

  Verinata Health Announces Agreement with Teva Pharmaceutical Industries in
  Collaboration with MOR Institute for Medical Data to Commercialize the
  verifi® Prenatal Test in Israel

      Agreement Establishes Patient Registry for Clinical Outcomes Data

Business Wire

REDWOOD CITY, Calif. -- July 1, 2013

Illumina, Inc. (NASDAQ: ILMN) today announced that Teva Pharmaceutical
Industries Ltd. signed an exclusive agreement with Verinata Health, an
Illumina company, for the commercialization of the verifi® non-invasive
prenatal test^1 in Israel. The MOR Institute for Medical Data Ltd., through
its relationship with Teva, will provide the verifi® prenatal test to
customers of Clalit Health Services who are at high risk of having a fetus
with a chromosomal abnormality. The MOR Institute, which is a wholly-owned
subsidiary of Clalit Health Services, will also establish a 9,000-patient
clinical outcomes registry to collect performance data and will share the data
with Verinata.

“We are extremely pleased to partner with Verinata in Israel, to bring
pregnant women unprecedented access to what we believe is the superior
non-invasive prenatal test to detect chromosomal abnormalities,” said Ron
Mayron, Chief Executive Officer of Teva Israel. “The verifi® prenatal test
exemplifies our investment in the women's health segment and our commitment to
offer clinically-validated, innovative new products to Israeli women to
improve their health and quality of life.”

Under the terms of the five-year agreement, Teva Pharmaceuticals will be the
exclusive distributor of the verifi® prenatal test in Israel. All tests will
be run in Verinata Health’s CLIA-certified laboratory in California. Clalit
Health Services will provide reimbursement for the verifi® prenatal test
through supplemental insurance.

“We strongly believe that the verifi® prenatal test will have a lasting and
positive impact on the Israeli community, and beginning July 1, MOR will
provide a special nursing service, allowing pregnant women to have their
sample collected for the test in the convenience of their homes, as well as in
MOR clinics in the country,” said Orit Jacobson, Ph.D., Chief Executive
Officer of MOR Institute. “The patient registry developed through this
collaboration will be the largest and most extensive of its kind,
demonstrating our commitment to leadership in women’s health.”

“This collaboration brings together the top healthcare marketing and sales
force in Israel with an established reimbursement infrastructure and long-term
performance measurements. The unique collaboration emphasizes the value of the
verifi® prenatal test,” said Vance Vanier, M.D., Vice President of Global
Commercial Operations for Verinata. “With the test now available in several
international markets, we look forward to expanding our commercial presence by
continuing to partner with leading organizations around the globe.”

About Verinata Health

Verinata (www.verinata.com), a wholly-owned subsidiary of Illumina, Inc., is
driven by a sole, extraordinary purpose – maternal and fetal health. Our
initial focus is to develop and offer non-invasive tests for early
identification of fetal chromosomal abnormalities using our proprietary
technologies. We aim to reduce the anxiety associated with today’s multi-step
process, the unacceptable false-positive rates, the non-specific and sometimes
confusing results of current prenatal screening methods, as well as the risk
of current invasive procedures. We support national guidelines and the recent
American College of Obstetricians and Gynecologists and the Society for
Maternal-Fetal Medicine Committee Opinion recommending cell-free DNA prenatal
testing is one option that can be used as a primary or secondary screening
test in women at increased risk of aneuploidy. We believe women who desire
such testing should be offered a single blood draw test with a definitive
result. The verifi^® prenatal test is available through a physician.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paying the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

^1 The verifi® prenatal test is a non-invasive blood test that analyzes DNA
found in a pregnant woman’s blood to detect the most common fetal chromosome
abnormalities, including Down syndrome (trisomy 21 or T21), Edwards syndrome
(trisomy 18 or T18), Patau syndrome (trisomy 13 or T13) and sex chromosome
abnormalities.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.